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Background/aim: Our study investigated the susceptibility rate of ceftazidime-avibactam and the risk factors associated with its
resistance by analyzing gram-negative bacteria isolated from various patient samples.
Materials and methods: Between March and November 2020, 1119 gram-negative bacteria strains were isolated from patient samples in
Acıbadem Healthcare Group hospitals; ceftazidime-avibactam susceptibility results were evaluated using a 10/4µg (Oxoid, UK) disc and
evaluated according to Eucast 2020 recommendations. Patient and isolate characteristics that could be risk factors were retrospectively
investigated and statistically analyzed using SPSS 25.0.
Results: Male patients made up 52% (n = 581) of the study’s total patient population, and they averaged 55.5 ± 24.9 years old. Of 1119
gram-negative strains culture and antibiogram, 1023 (91.4%) were sensitive to ceftazidime-avibactam. An increased risk of resistance
was observed with female gender (OR = 2.29; CI 95% [1.45–3.61]; p < 0.05), Pseudomonas aeruginosa (OR = 1.67, CI 95% [1.03–2.7]; p
< 0.05), the presence of multidrug-resistance (MDR) (OR = 4.07, CI 95% [2.47–6.7]; p < 0.05) pandrug-resistance (PDR) (OR = 12, (CI)
95% [9.9–14.7] ]; p < 0.05) and admission to intensive care unit (ICU) (OR = 1.89, CI 95% [1.22–2.93]; p < 0.05).
Conclusion: The resistance rate of ceftazidime-avibactam was found to be 8.6%, and it was thought that resistant strains produced
metallo-ß-lactamase (MBL) type carbapenemase. Risk factors were female gender, Pseudomonas aeruginosa, MDR, PDR, and admission
to ICU. Therefore, studying the ceftazidime-avibactam susceptibility test together with gram-negative bacteria identification, especially
in groups at risk for resistance, is one of the important factors that can positively affect the success of treatment.
Key words: Antimicrobial agents, drug-resistant, multidrug-resistant, ceftazidime-avibactam combination, gram-negative bacteria

1.Introduction
Infections caused by antibiotic-resistant bacteria are one
of the most serious public health challenges [1,2]. At
the beginning of the 2000s, multidrug-resistant grampositive bacteria were the most concerning; however,
resistance gram-negative bacteria are now the center of
attention [3]. These bacteria produce infectious diseases
that are linked with considerable mortality and morbidity.
Each year, more than 23,000 people in the United States
die as a result of diseases caused by multidrug-resistant
bacteria. When they researched these microbes, they
discovered extended-spectrum beta-lactamase (ESBL)

and carbapenemase producing Enterobacteriaceae, as well
as multidrug-resistance (MDR) Acinetobacter baumannii
and Pseudomonas aeruginosa [4]. Antibiotic resistance
in gram-negative bacteria is mainly caused by enzymes
that alter the structure of antibiotics, such as Amp C,
cephalosporinase, ESBL, and carbapenemase [2]. It is
well recognized that plasmid or transposon-mediated
distribution promotes these resistance characteristics.
The World Health Organization has warned that ESBL
and carbapenemase-producing gram-negative bacteria,
in particular, may cause intractable infectious disease and
increased mortality [5]. Because the number of antibiotics
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available to treat carbapenem-resistant Enterobacteriaceae
(CRE) is limited, it has become critical to seek for other
antibiotic options. As a result of these advances, several
novel antibiotic and combination treatment options
have emerged in recent years [6]. One of these new
combinations is the ceftazidime-avibactam combination.
Avibactam is a nonbeta lactam, diazobicyclooctanebeta lactamase inhibitor. It is effective against metallobeta-lactamases (MBL) from classes A, C, and D, but
has minimal activity against MBL from class B. As a
consequence, ceftazidime-avibactam has significant
antimicrobial action against CRE and P. aeruginosa,
but only moderate antimicrobial activity against A.
baumannii, gram-positive bacteria, and anaerobic
bacteria. Ceftazidime-avibactam combination is FDAapproved for treating severe urinary tract infections,
intra-abdominal
infections,
ventilator-associated
pneumonias, and healthcare-associated pneumonias
[7]. In Turkey, Class D Oxacillinase (OXA) is the most
common carbapenemase type, making ceftazidimeavibactam a potential therapy for carbapenem-resistant
gram-negative infections [8,9]. However, studies show
that resistance to ceftazidime-avibactam can develop with
or without medication exposure [10,11]. Our goal was to
gain a general understanding of ceftazidime-avibactam
susceptibility at several hospitals in İstanbul, Turkey, and
to identify risk factors associated with resistance.
2. Materials and methods
2.1. Study design
A total of 1119 gram-negative isolates obtained from several
Acıbadem Healthcare Group hospitals in İstanbul, Turkey
were retrospectively evaluated. All susceptibility tests were
performed at Acıbadem Labmed Central Microbiology
Laboratory with the Kirby-Bauer disc diffusion method,
ceftazidime-avibactam 10/4 µg (Oxoid, UK) disc, and
carbapenemase generation with 10 µg meropenem (BD
BBLTM, USA) disc were utilized. All of the preceding steps
incorporated Eucast 2020 recommendations. Patient
demographic variables, including age, gender, sample type,
infecting microorganisms, and admission department
were collected. The resistance pattern of the strains was
separated into two categories based on the antibiogram
results: those with multiple antibiotic resistance and those
without multiple resistance. Multiple resistance groups
were identified in the study, including MDR (resistance
to three or more antibiotic classes), XDR (maximally
susceptible to two antibiotic classes), and PDR (resistance
to all antibiotics).
2.2. Ethical approval and statistical analysis
This study was approved by the Acıbadem University
Ethics Committee (date 14.10.2021/no 2021-20/18).
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All the frequencies, including susceptibility and
resistance to ceftazidime-avibactam, were provided as a
percentage for each material type, microorganism type,
ESBL and carbapenemase production, and drug resistance
type. Crosstabs were used to show the relationship between
variables such as age, department groups, and ceftazidimeavibactam susceptibility. The odds ratio for risk variables
that impact ceftazidime-avibactam susceptibility and
resistance was calculated using the chi-squared test. The
SPSS 25.0 (Statistical Package for Social Sciences) program
was used to conduct the statistical analysis.
3. Results
The demographic variables of the study include patients
of both genders and belonging to numerous age groups.
Among the patients 52% (n = 581) were male, 48% (n =
538) were female and the mean age was 55.5 ± 25.9 (min: 0
max: 97). 1023 (91.4%) strains are sensitive to ceftazidimeavibactam. When compared to other sample types,
blood samples had the lowest sensitivity for ceftazidimeavibactam by 87.5%. 82% of the carbapenemaseproducing gram-negative bacteria were sensitive to
ceftazidime-avibactam and 7.2% of the resistant strains
(60/837) were isolated from patients treated in clinical
departments, whereas 12.8% (36/282) were from patients
treated in intensive care units, (p < 0.05). Ceftazidimeavibactam resistant strains were found in 8.7% (43/496)
of geriatric patients (≥ 65 years old) while 8.5% of (<65
years old) (53/623) nongeriatric patients, (p > 0.05). Table
1 shows the ceftazidime-avibactam sensitivity ratio sorted
by sample types, while Table 2 shows the sensitivity ratio
sorted by microorganism type and resistance pattern.
Females had an odds ratio of 2.29, while the presence
of P. aeruginosa, MDR, PDR, and ICU admission has 1.67,
4.07, 12, and 1.89, respectively. The odds ratio of the factors
that affect ceftazidime-avibactam is presented in Table 3.
4. Discussion
The ceftazidime-avibactam combination has received
FDA approval in 2019 for the treatment of healthcareassociated ventilator-associated pneumonia, intraabdominal infections and urinary tract infections caused
by multi-drug resistant gram-negative bacilli [7]. This
combination was granted a license in Turkey in 2019 [12],
however it will not be included in the reimbursement
health assurance system until April 28, 2021.
Prior to this date, ceftazidime-avibactam susceptibility
rates of gram-negative bacteria isolated from various
samples of patients followed in a private Acıbadem
Healthcare Group hospitals between March-November
2020. At that time, the use of combination was limited
to a few private health institutions. In general, resistance
rises steadily as consumption rises [10,11]. As a result,
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we intended to investigate the susceptibility of this
combination prior to its widespread use, in order to serve
as a base for the future research.
The
ceftazidime-avibactam
resistant
strains
obtained from patient samples who are naive to this
combination were studied in a multicenter study
conducted in the United States between 2013 and 2016.
Basal resistance was discovered to be primarily induced
by intrinsic resistance generating MBL, and very rarely by
porin mutation (OmpK36) [13].
In Turkey, molecular methods revealed that the
dominant carbapenemase type is OXA-48, and MBL such
as New Delhi metallo-beta-lactamase (NDM) and Verona
integron-borne metallo-lactamase (VIM) are rarely found
[14]. This situation leads us to believe that the combination
of ceftazidime-avibactam may be an effective treatment for
multidrug-resistant gram-negative bacterial infections in
our country.

Another study from Turkey found that 95.2% of 84
enteric bacterial strains expressing OXA-48 the most
common kind of carbapenemase and K. pneumoniae
carbapenemase (KPC) were susceptible to ceftazidimeavibactam [15]. The sensitivity of all gram-negative
isolates to ceftazidime-avibactam was found to be 91.4%
during our study duration. Using a liquid micro-dilution
approach, ceftazidime-avibactam resistance was shown to
be 20.1% in research including 167 K. pneumonia strains
with carbapenem resistance [16]. In our study, 18% of
gram-negative isolates with carbapenem resistance were
resistant to ceftazidime-avibactam.
Another study, conducted in 2017 on 872 K.pneumoniae
strains in China prior to the drug’s market entry, found
that ceftazidime-avibactam resistance was only 3.7%.
The resistant strains produced 53.1% MBL, 40.6% KPC
type carbapenemase, and 6.3% produced both MBL and
KPC [17]. Another study found that clinical success rates

Table 1. Ceftazidime-avibactam sensitivity ratio according to sample types.
Sample types

% (n)

Ceftazidime-avibactam sensitivity% (n)

Urine

33.3% (n = 372)

93.2% (n = 347)

Trachea/aspirate culture

24.6% (n = 275)

90.5% (n = 49)

Pus

17.2% (n = 192)

89.5% (n = 172)

Blood

13%(n = 144)

87.5% (n = 126)

Biological fluid

4.5% (n = 50)

96.0% (n = 48)

Catheter

1.9% (n = 22)

95.4% (n = 21)

Biopsy material

1.5% (n = 17)

94.1% (n = 16)

Cerebrospinal fluid

0.2% (n = 3)

100% (n = 3)

Others

3.9% (n = 44)

93.1% (n = 41)

Total isolates

100% (n = 1119)

91.4% (n = 1023)

Table 2. Ceftazidime-avibactam sensitivity ratio according to microorganism type and resistance pattern.
Microorganism type/ resistance pattern

% (n)

Ceftazidime-avibactam sensitivity% (n)

Enterobacteria

65% (n = 728)

91% (n = 663)

Klebsiella spp.

61% (n = 680)

92% (n = 626)

Other enteric bacilli

4%(n = 48)

77% (n = 37)

Pseudomonas spp.

35% (n = 391)

92% (n = 359)

ESBL(+), Carbapenemase(-)

16% (n = 116)

99% (n = 115)

Carbapenemase(+)

47% (n = 345)

82% (n = 283)

Without multiple resistance

32.5% (n = 238)

100% (n = 238)

MDR

40% (n = 293)

95% (n = 278)

XDR

27% (n = 193)

78% (n = 148)

PDR

0.5% (n = 4)
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Table 3. Risk factors for development of Ceftazidime-avibactam resistance.
Odds ratio

Lower limit

Upper limit

P-value

Gender
Female/male

2.29

1.45

3.61

<0.001

Pseudomonas aeruginosa
Present/absent

1.67

1.03

2.7

<0.05

MDR
Present/absent

4.07

2.47

6.7

<0.05

PDR
Present /absent

12

9.9

14.7

<0.05

Intensive care unit

1.89

1,22

2.93

<0.05

for ceftazidime-avibactam combinations ranged from
45% to 100% [18]. In our study, the sensitivity of gramnegative Enterobacteriaceae and P. aeruginosa isolates to
ceftazidime-avibactam was determined to be 91% and
92% respectively. Another research reveals that using a
combination of ceftazidime-avibactam for the treatment
of P. aeruginosa resulted in an effective clinical response
in 86.7% of the patients [19]. Similar to our study, a
multicenter study conducted between 2016 and 2018
found that 92% of P. aeruginosa isolates were sensitive to
ceftazidime-avibactam. The same study revealed that the
rates of resistance varied greatly by region, ranging from
6% in Europe to 53.2% in South America [20]. A study
reported that a total of 18.5% of 54 clinical P. aeruginosa
isolates resistant to a variety of beta-lactam antibiotics
were also resistant to ceftazidime-avibactam [21].
According to research conducted in Germany, 64.1%
of multidrug-resistant/extensively drug-resistant (MDR/
XDR) P. aeruginosa were responsive to ceftazidimeavibactam [22]. In our study, ceftazidime-avibactam
sensitivity was found to be 95% for MDR bacteria and 78%
for XDR bacteria. Additionally, we found that belonging to
the MDR and XDR class bacteria group is considered a risk
factor for ceftazidime-avibactam resistance. Furthermore,
all four PDR isolates tested positive for ceftazidimeavibactam resistance.
In our study, the isolates were separated into groups
based on the kind of sample and the patient’s admission
to either intensive care unit (ICU) or clinical service. The
susceptibility rates were lower in the blood sample and in
samples taken from patients admitted to ICU. Furthermore,
risk factor analysis showed that being admitted to the
intensive care unit approximately double the risk for
ceftazidime-avibactam resistance. A researchevaluated the
antimicrobial susceptibility of gram-negative bacteria from
intensive care unit and nonintensive care unit patients in
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United States hospitals and found that susceptibility rates
of several antibiotics were usually lower in ICU patients
compared to non-ICU patients [23].
Female gender, the isolated agent being P. aeruginosa,
and the agent being from MDR or PDR resistance
group were other risk factors for ceftazidime-avibactam
resistance in our study while pneumonia and renal
replacement were the risk factors for ceftazidimeavibactam resistance according to Ryan and his colleagues
[24]. We could not make any judgments on renal function
since our study did not include any clinical data about the
patients’ kidney functions. From this standpoint and as
a result, identifying patient groups at risk of developing
resistance and conducting susceptibility tests for them
is critical to avoiding treatment failure. The molecular
analysis of carbapenemase types in the strains was not
possible in our study because we used retrospective data
from diagnostic routine tests and molecular analysis did
not involve in this routine, which was a limitation of
our study. Although this is one of our study limitations,
future ceftazidime-avibactam susceptibility studies,
in which molecular analysis can be used, will provide
meaningful contributions to the literature. Our study,
which included 1119 gram-negative bacteria strains
isolated from patients who were followed up and treated
in hospitals affiliated with a private health group, provides
baseline resistance data in the population prior to the
widespread use of ceftazidime-avibactam in Turkey. In
our study this combination has high susceptibility rates
compared to the available data from literature, indicating
that it is a promising agent for the treatment of drugresistant gram-negative bacteria. Antibiotic resistance
increased dramatically with increased consumption [25],
necessitating future research to evaluate the ceftazidimeavibactam sensitivity in the period following its frequent
consumption in Turkey.

DUMLU et al. / Turk J Med Sci
Ceftazidime-avibactam still has a high susceptibility
rate, making it an excellent alternative for last-line therapy
in the treatment of resistant gram-negative bacterial
infections. However, resistance is evolving, which is
considered a danger in females and in the presence of P.
aeruginosa, MDR, PDR isolates, and patients admitted to
ICU. More research is needed to determine the optimal
approaches for avoiding future resistance based on our
data.
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